Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173254
Title: | The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes |
Author: | Cuyàs, Elisabet Gumuzio, Juan Verdura, Sara Brunet, Joan Bosch Barrera, Joaquim Martín Castillo, Begoña Alarcón Cor, Tomás Encinar, José Antonio Martin, Ángel G. Menendez, Javier A. |
Keywords: | Epigenètica Càncer de mama Epigenetics Breast cancer |
Issue Date: | 1-Jan-2020 |
Publisher: | Impact Journals Llc. |
Abstract: | SOX2 is a core pluripotency-associated transcription factor causally related to cancer initiation, aggressiveness, and drug resistance by driving the self-renewal and seeding capacity of cancer stem cells (CSC). Here, we tested the ability of the clinically proven inhibitor of the lysine-specific demethylase 1 (LSD1/KDM1A) iadademstat (ORY-100) to target SOX2-driven CSC in breast cancer. Iadademstat blocked CSC-driven mammosphere formation in breast cancer cell lines that are dependent on SOX2 expression to maintain their CSC phenotype. Iadademstat prevented the activation of an LSD1-targeted stemness-specific SOX2 enhancer in CSC-enriched 3-dimensional spheroids. Using high-throughput transcriptional data available from the METABRIC dataset, high expression of SOX2 was significantly more common in luminal-B and HER2-enriched subtypes according to PAM50 classifier and in IntClust1 (high proliferating luminal-B) and IntClust 5 (luminal-B and HER2-amplified) according to integrative clustering. Iadademstat significantly reduced mammospheres formation by CSC-like cells from a multidrug-resistant luminal-B breast cancer patient-derived xenograft but not of those from a treatment-naive luminal-A patient. Iadademstat reduced the expression of SOX2 in luminal-B but not in luminal-A mammospheres, likely indicating a selective targeting of SOX2-driven CSC. The therapeutic relevance of targeting SOX2-driven breast CSC suggests the potential clinical use of iadademstat as an epigenetic therapy in luminal-B and HER2-positive subtypes. |
Note: | Reproducció del document publicat a: https://doi.org/10.18632/aging.102887 |
It is part of: | Aging-us, 2020, vol. 12, num. 6, p. 4794-4814 |
URI: | http://hdl.handle.net/2445/173254 |
Related resource: | https://doi.org/10.18632/aging.102887 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
CuyasE.pdf | 2.14 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License